Stockhead on MSN55m
Dr Boreham’s Crucible: FDA approval blasted this regenerative biotech higher in 2024… so what’s next?
Fresh from FDA approval for its stem-cell product for paediatric graft-versus-host disease, Mesoblast is pursuing consent for ...